Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Real-time Estimate Cboe BZX  -  09:46 2022-12-06 am EST
3.515 USD   +0.14%
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-HodgkinÔÇÖs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Number of employees : 312 people.
Sales per Business
20202021Delta
Antibody Drug Conjugates--33.92100%-
USD in Million
Managers
Name Title Age Since
Ameet Mallik President, Chief Executive Officer & Director 49 2022
Jennifer Creel Chief Financial Officer 50 2020
Patrick van Berkel Chief Scientific Officer 53 -
Joseph S. Camardo, Dr. Chief Medical Officer 66 -
Michael Mulkerrin, Dr. Chief Technical Operations Officer - -
Susan Romanus Chief Compliance & Quality Officer 56 -
Amanda Hamilton Head-Investor Relations - -
David Gilman Chief Business & Strategy Officer - 2022
Kristen Harrington-Smith Chief Commercial Officer 48 2022
Michael Forer Vice Chairman, Executive VP & General Counsel 56 2020
Members of the board
Name Title Age Since
Ron Squarer Chairman 54 2020
Peter Corr Independent Non-Executive Director 73 2020
Stephen Ralfe Evans-Freke Independent Non-Executive Director 69 2011
Jacques Theurillat Independent Non-Executive Director 63 2015
Thomas Pfisterer Independent Non-Executive Director 39 2016
Thomas M. Rinderknecht, Dr. Independent Non-Executive Director 67 2016
Peter Hug, Dr. Independent Non-Executive Director 63 2019
Tyrell J. Rivers, Dr. Independent Non-Executive Director 48 2018
Victor Sandor, Dr. Independent Non-Executive Director 54 2020
Viviane Monges Independent Non-Executive Director 59 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,270,000 36,705,637 46.9% 1,459,522 1.9% 46.9%
Shareholders
NameEquities%
Auven Therapeutics Management LLLP 21,415,605 27.9%
Redmile Group LLC 7,512,029 9.78%
Fidelity Management & Research Co. LLC 6,489,037 8.45%
AstraZeneca PLC 4,011,215 5.22%
AllianceBernstein LP 2,915,160 3.80%
Deerfield Management Co. LP 2,390,297 3.11%
JPMorgan Investment Management, Inc. 2,201,436 2.87%
Eventide Asset Management LLC 1,879,959 2.45%
Christopher John Martin 1,731,999 2.25%
Grosvenor Capital Management LP 1,517,212 1.98%
Company contact information
ADC Therapeutics SA
Biop˘le
Route de la Corniche 3B
Epalinges, Vaud 1066

Phone : +41.212.653.02.00
Web : http://www.adctherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of ADC Therapeutics SA